These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Basiliximab induction in renal transplantation: long-term outcome. Atlani M; Sharma RK; Gupta A Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617 [TBL] [Abstract][Full Text] [Related]
45. Comparison between spousal donor transplantation treated with anti-thymocyte globulin induction therapy and, living related donor transplantation treated with standard immunosuppression. Demir E; Paydas S; Erken U Saudi J Kidney Dis Transpl; 2014 May; 25(3):520-3. PubMed ID: 24821146 [TBL] [Abstract][Full Text] [Related]
46. Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients. Majernikova M; Rosenberger J; Prihodova L; Jarcuskova M; Roland R; Groothoff JW; van Dijk JP Biomed Res Int; 2017; 2017():6987240. PubMed ID: 28401160 [No Abstract] [Full Text] [Related]
47. Prevalence and association of post-renal transplant anemia. Elsayed H; Sany D; Eldin EN; El-shahawy Y; Shawki S; Aziz A Saudi J Kidney Dis Transpl; 2012 May; 23(3):461-6. PubMed ID: 22569428 [TBL] [Abstract][Full Text] [Related]
48. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial. Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H; Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107 [TBL] [Abstract][Full Text] [Related]
49. Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis. Jones H; Talwar M; Nogueira JM; Ugarte R; Cangro C; Rasheed H; Klassen DK; Weir MR; Haririan A Transplantation; 2012 May; 93(9):923-8. PubMed ID: 22377790 [TBL] [Abstract][Full Text] [Related]
50. Proteinuria is a predictor of posttransplant anemia. Bonofiglio R; Lofaro D; Greco R; Senatore M; Papalia T Transplant Proc; 2011 May; 43(4):1063-6. PubMed ID: 21620053 [TBL] [Abstract][Full Text] [Related]
52. Outcome of sirolimus-based immunosuppression, fifteen years post-live-donor kidney transplantation: Single-center experience. Hamdy AF; Elhadedy MA; Donia AF; Taha NM; Bakr MA Clin Transplant; 2019 Feb; 33(2):e13463. PubMed ID: 30548935 [TBL] [Abstract][Full Text] [Related]
53. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543 [TBL] [Abstract][Full Text] [Related]
54. Frequency of the Original Kidney Disease and Its Effect on the Outcome of Kidney Transplant in the Urology-Nephrology Center Mansoura University. Mashaly ME; Ismail MI; Lotfy EE; Donia AF; Wafa IW; Foda MA; Denewar AA; Abbas MH; Shokeir AA Exp Clin Transplant; 2016 Apr; 14(2):157-65. PubMed ID: 26788876 [TBL] [Abstract][Full Text] [Related]
55. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670 [TBL] [Abstract][Full Text] [Related]
56. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959 [TBL] [Abstract][Full Text] [Related]
57. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963 [TBL] [Abstract][Full Text] [Related]
58. Post-Transplant Anemia Has Strong Influences on Renal and Patient Outcomes in Living Kidney Transplant Patients. Ichimaru N; Obi Y; Nakazawa S; Yamanaka K; Kakuta Y; Abe T; Kaimori JY; Imamura R; Nonomura N; Moriyama T; Takahara S Transplant Proc; 2016 Apr; 48(3):878-83. PubMed ID: 27234757 [TBL] [Abstract][Full Text] [Related]
59. Kaposi's sarcoma after renal transplantation. Abbaszadeh S; Taheri S Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):775-8. PubMed ID: 19736472 [TBL] [Abstract][Full Text] [Related]
60. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Kim YS; Moon JI; Kim SI; Park K Transplantation; 1999 Aug; 68(4):578-81. PubMed ID: 10480420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]